Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China

Collaboration to accelerate the development and access of oncology medicines for cancer patients in China Clinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent…